Cart
sales@molnova.com
Lodenafil
CAS No. 139755-85-4
Lodenafil ( Hydroxyhomosildenafil )
Catalog No. M20715 CAS No. 139755-85-4
Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 60 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 147 | In Stock |
|
| 25MG | 293 | In Stock |
|
| 50MG | 509 | In Stock |
|
| 100MG | 711 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLodenafil
-
NoteResearch use only not for human use.
-
Brief DescriptionLodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
-
DescriptionLodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
-
SynonymsHydroxyhomosildenafil
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number139755-85-4
-
Formula Weight504.6
-
Molecular FormulaC23H32N6O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (495.44 mM)
-
SMILESCCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CCO)CC1
-
Chemical Name5-(2-Ethoxy-5-((4-(2-hydroxyethyl)-1-piperazinyl)sulfonyl)phenyl)-16-dihydro-1-Methyl-3-propyl-7H-pyrazolo(43-d)pyriMidin-7-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Polonio I B Acencio M M P Pazetti Rogério et al. Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats[J]. Jornal Brasileiro de Pneumologia 2014 40(4):421-424.
molnova catalog
related products
-
LJI308
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
Cilostazol
Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo.
-
MBCQ
MBCQ is an inhibitor of cGMP-specific phosphodiesterase PDE5.MBCQ, a selective PDE5 inhibitor, significantly decreased the EC(50) values for GTN-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift occurring in tolerant veins.
